PMID- 15801034
OWN - NLM
STAT- MEDLINE
DCOM- 20050711
LR  - 20151119
IS  - 0315-162X (Print)
IS  - 0315-162X (Linking)
VI  - 32
IP  - 4
DP  - 2005 Apr
TI  - Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment 
      with etanercept.
PG  - 740-3
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents 
      that neutralize TNF-alpha are effective in the treatment of disorders such as 
      rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, 
      and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated 
      with the development of antinuclear antibodies (ANA) and double-stranded DNA 
      (dsDNA) antibodies, as well as the infrequent development of systemic lupus 
      erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed 
      proliferative lupus nephritis and leukocytoclastic vasculitis in a patient 
      treated with etanercept for JRA.
FAU - Mor, Adam
AU  - Mor A
AD  - Division of Rheumatology, Department of Medicine, New York University School of 
      Medicine/Hospital for Joint Diseases, New York, New York, USA. mora01@med.nyu.edu
FAU - Bingham, Clifton O 3rd
AU  - Bingham CO 3rd
FAU - Barisoni, Laura
AU  - Barisoni L
FAU - Lydon, Eileen
AU  - Lydon E
FAU - Belmont, H Michael
AU  - Belmont HM
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Recombinant Fusion Proteins)
RN  - OP401G7OJC (Etanercept)
SB  - IM
EIN - J Rheumatol. 2014 Nov;41(11):2336. Bingham, Clifton 3rd [corrected to Bingham, 
      Clifton O 3rd]
MH  - Adult
MH  - Antirheumatic Agents/*adverse effects/immunology
MH  - Arthritis, Juvenile/*complications/drug therapy
MH  - Disease-Free Survival
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunoglobulin G/*adverse effects/immunology
MH  - Lupus Nephritis/*chemically induced/immunology/pathology
MH  - Receptors, Tumor Necrosis Factor/immunology
MH  - Recombinant Fusion Proteins/*adverse effects/immunology
MH  - Vasculitis, Leukocytoclastic, Cutaneous/*chemically induced/immunology/pathology
MH  - Withholding Treatment
EDAT- 2005/04/01 09:00
MHDA- 2005/07/12 09:00
CRDT- 2005/04/01 09:00
PHST- 2005/04/01 09:00 [pubmed]
PHST- 2005/07/12 09:00 [medline]
PHST- 2005/04/01 09:00 [entrez]
AID - 0315162X-32-740 [pii]
PST - ppublish
SO  - J Rheumatol. 2005 Apr;32(4):740-3.